The task of cataloging human genetic variation and its relation to disease is rapidly approaching completion. The new challenge is to discover the function of disease-associated genes and to understand the pathways that lead to human disease. We propose that achieving this new level of understanding will increasingly rely on the use of model organisms. We discuss the advantages of the mouse as a model organism to our understanding of human disease.
INTRODUCTION
Most common human diseases involve loss of homeostatic control across multiple organ systems. Various metabolic organs, such as brain, stomach, liver, adipose, and muscle, interact in complex, poorly understood ways to integrate and coordinate activities throughout life and across environments. The ongoing challenge is to identify the genetic variants that control function of individual elements and their complex interactions [1, 2] .
Rapid improvements in DNA sequencing technology and phenotyping capacity have accelerated the pace at which human genetic variation is characterized. Through the efforts of research groups across the globe, the formidable task of cataloging human allelic and haplotype variation is rapidly reaching completion [3] [4] [5] . Now, the challenge is to leverage these technologies and resources to systematically define the ways in which genotypes define phenotypes in health and the ways that dysfunction lead to disease.
We propose that an understanding of health and disease depends on experimental examination of genotype-phenotype relations in model organisms. As our understanding of human disease moves past 'gene discovery', we predict that the groundbreaking discoveries required to unravel the complex basic biology of human health and disease will increasingly rely on research in model organisms. To support our argument, we review selected highlights of past discoveries from studies related to obesity and diabetes in mouse models and then look ahead at new developments in model systems that will help us push beyond the limitations of the past.
WHY STUDY MICE?
Mouse models have made significant contributions to our understanding of human biology and disease over the past century [6] . These contributions have been based on the similarity between humans and mice in development, physiology, and genome organization, as well as access to engineered mutants, phenotyping platforms, and genetic reference populations. The efficacy of such cross-species studies was recently demonstrated for $4500 metabolic, physiological, pharmacological, and behavioral traits [7] .
Homology
Homologous physiology and morphology between humans and mice enables the study of human diseases in a mammalian surrogate that is amenable to laboratory experimentation. Even when phenotypic differences are evident, the underlying pathways are remarkably similar. For example, there is deep homology in insulin biology that is found throughout the animal kingdom. Insulin has the same molecular structure in humans, mice, and fruit flies. The insulin secretory pathway is also remarkably similar, involving the storage of a secretory pool of insulin in granules and their trafficking to the plasma membrane after an appropriate stimulus. Homology is also found in the insulin signaling system, involving the insulin receptor, its tyrosine kinase activity, its downstream substrates, and the regulation of growth and metabolism.
Genomics
Various attributes make the laboratory mouse a good model for studying genetics of human biology in health and disease. The relevance of model organisms to studies of human biology is evident in the highly conserved genetic content, protein functions, and metabolic and signaling pathway topologies. The important exceptions contribute to discrepancies between genotype-phenotype relations. It is important to note that conclusions about the relevance of mouse models to human biology are often based on studies of a small number of strains, and often only one strain. Generalizations across strains are risky given the considerable phenotypic variation across strains, which is documented in the Mouse Phenome Database (jax.org/phenome).
Mutations
Another important attribute is the ability to engineer mutations [8] . With clustered regularly interspersed short palindromic repeats (CRISPR)/ CRISPR-associated system (Cas9) technologies, a remarkable variety of mutations can be made in a highly efficient and cost-effective manner. These include gain and loss-of-function, inducible, conditional, and tissue-specific mutations as well as reporter constructs to signal when and where a gene is expressed. Targets include both protein coding genes as well as noncoding regulatory RNAs and structural elements. International efforts are underway to establish a comprehensive public resource with cells and mice with engineered mutations as well as associated phenotypes. These and other technologies can also be used to 'humanize' mice by introducing specific human DNA sequence variants as a way to test causation and functional relevance as well as undertake mechanistic studies [9] [10] [11] .
Tissue access
The mouse also provides opportunities to obtain tissues from test and control groups in ways that can be logistically challenging or ethically inappropriate in humans. In many cases, access to specific tissues at particular developmental and life-history stages is needed. For many metabolic conditions, however, organ and tissue samples such as liver biopsies from healthy individuals for comparison with disease states are usually difficult to obtain. In most instances, mice resolve this dilemma, with materials from precisely defined test and control groups.
Phenotyping
Systematic high-throughput phenotyping programs have been established based on common protocols, ontologies, technologies, and analyses, as ways to improve generality and reproducibility [9] [10] [11] .
Genetic resources
Finally, by using designed populations of mice, we can minimize environmental heterogeneity, population stratification, unknown ancestral haplotypes, and unbalanced allele frequencies, which can complicate human genome-wide association studies in humans. With newly developed mouse resources, it is now possible to achieve power and mapping resolution of tens of thousands of humans with only hundreds of mice.
IMPOSSIBLE WITHOUT A MUTANT MOUSE

Two classic discoveries
Leptin; insightful physiology, genetic triumph, epistatic interactions Long before gene discovery was feasible, physiological studies led to insights not only about satiety control, but also about hormonal regulation of multiorgan systems and gene interaction networks that coordinate metabolic activities. Two spontaneous mutations arose in mice at the Jackson Laboratory, obesity (ob) in 1950 [12] and diabetes (db) in 1965 [13] . The mutant mice are both obese and hyperinsulinemic [14] . Coleman [15] conducted parabiosis experiments, where the circulatory systems of db or ob mice were surgically connected to that of normal mice (test) or to each other (control). When the db mouse was paired with a normal mouse or an ob mouse, the ob mouse died of starvation (Fig. 1a) . But when an ob mouse was paired with a normal mouse, the normal mouse was unaffected. Coleman hypothesized that the ob mouse lacked a circulating satiety factor and the db mouse lacked the receptor for that factor. This hypothesis proved to be prescient with the cloning of leptin and its receptor decades later [16, 17] .
The parabiosis paradigm has proved useful in other contexts. For example, Kulkarni and coworkers discovered that mice with a liver-specific deletion of the insulin receptor experienced a dramatic enhancement in b-cell proliferation [18] . Parabiosis was used to determine whether a soluble factor, presumably liver-derived, stimulates b-cell proliferation (Fig. 1b) . Their studies eventually led to the identification of Serpin B1 as a circulating mitogenic factor [19] .
Leptin is produced in adipose tissue. Prior to its discovery, adipose tissue had not been regarded as an endocrine organ. The discovery of additional adipose-derived hormones; for example, adiponectin [20] , RNA binding protein 4 [21] , and resistin [22] , blurred the boundaries between endocrine and nonendocrine organs. Soon, other hormones were identified, secreted by tissues not usually regarded as endocrinal, such as muscle, bone, macrophages, liver, stomach, and the intestine. This has led to a paradigm shift, where most tissues and organs are now considered to have endocrine activity.
Agouti, a novel pathway and pleiotropy
The Agouti mutation is an excellent example of genetics solving a riddle not amenable to a simple hypothesis. The Agouti-yellow mutation has pleiotropic effects; it causes obesity and yellow hair. The agouti protein is normally produced in dermal papillae cells and functions in a paracrine fashion to antagonize the action of a-melanocyte stimulating hormone on melanocytes. This prevents the stimulation of melanin production via the melanocortin-1 receptor, which leads to black hair and results in the production of phaeomelanin, leading to yellow hair. The obesity phenotype is caused by ectopic production of the Agouti protein in the brain, leading to the antagonism of a-melanocyte stimulating hormone binding to the melanocortin-4 receptor (MC4R). Based on homology to the Agouti protein, the Agouti-related protein was identified and found to be the normal physiological ligand of the MC4R in the hypothalamus, where it functions to suppress feeding [23] . Mutations in the MC4R are the most common genetic cause of obesity in humans and the receptor is a target for drugs to treat obesity [24] .
Genetics of multifactorial metabolic traits
Unlike the ob and db mutations, which have unusually large, consistent phenotypic effects, most genetic variants have relatively modest phenotypic effects in natural populations. By identifying these genes, clues are obtained about molecular and physiological functions. With genes that control complex traits, the powerful technologies and resources of laboratory mice can be used to deconstruct these traits. For example, several genes have been identified that affect different steps in the insulin secretory pathway [25, 26] , b-cell proliferation [27] , and insulin signaling [28] .
The vast majority of loci that contribute to phenotype variation are quantitative trait loci (QTLs), where multiple genes acting independently or interactively (epistasis) determine the phenotypic nature of the trait. Until recently, the path from mapping a locus to identifying a causal gene was arduous because the mapping resolution was modest in conventional crosses between pairs of strains. Only with follow-up crosses to capture additional recombinants could the resolution be narrowed to identify candidate genes [29] . New developments in genetic resources have accelerated the pace of QTL detection and gene identification. Similarly, genome sequencing and genetic engineering technologies have accelerated gene identification and Understanding obesity and diabetes genetics Attie et al.
validation. As a result, gene discovery, not simply localization, is now routine, exceeding genomewide association studies at a far lower cost [30] .
Modifier genes and gene interactions
The pioneering studies by Coleman and colleagues also showed that strain background interacted with the ob mutation to determine whether mice would also become diabetic. In particular, db or ob mice on the C57BL/6J background are nondiabetic, whereas db or ob mice on the C57BL/Ks background become diabetic [31] . As the genetic modifiers of phenotypes in db and ob mice suggest, genes rarely act alone, but instead are part of complex webs of interactions, not simply in pathways but also in networks of functional interdependencies that provide resilience to stress, adverse environmental exposures, [18, 19] . LIRKO, liver insulin receptor knockout.
and suboptimal genetic backgrounds. Although evidence for these modifier genes in mice and humans is now considerable [32, 33] , evidence for more complex gene interactions has been more elusive, especially in humans. However, surveys of hundreds of traits in a chromosome substitution strain (CSS) panel showed that these interactions are pervasive and strong [34 & ]. These studies took advantage of the unique genetic architecture of these strains. Now the challenge is finding ways to detect modifier and epistatic effects in mouse crosses and human populations. These studies are important because modifiers that suppress disease risk and adverse phenotypic outcomes could be a new class of therapeutic targets given their obvious efficacy and apparent safety.
Epigenetic inheritance
Epigenetic inheritance, which is revolutionizing our understanding of the origins of phenotypic variation, occurs in the absence of inherited genetic variants and without persistent environmental exposures [35] [36] [37] . In these cases, yet to be identified molecular changes in the germline lead to inherited phenotypic variants that can persist for generations and that can sometimes be reversed with specific crosses. Examples of epigenetic traits related to metabolic conditions involve obesity [38] [39] [40] [41] glucose homeostasis [42, 43] , lipid metabolism [44] , and microbiota [45] . Genetic factors also contribute. For example, a genetic variant in a strain that is resistant to diet-induced metabolic conditions epigenetically transferred resistance to a genetically susceptible strain with resistance persisting for multiple generations and reversible with specific crosses [46 & ]. These unexpected results suggest that the ongoing epidemic of metabolic disease may have genetic and environmental origins in early life and in preceding generations [44] . The challenge now is to identify the molecular basis for epigenetic inheritance as well as to establish the chain of causality that leads from somatic exposures to environmental factors and genetic variants through heritable epigenetic changes in the germline to phenotypic variation in later generations. These experiments are complex, involving rigorous control of genetics and environment so that specific factors can be manipulated and their consequences evaluated. These remarkable discoveries will no doubt lead to exciting new strategies for therapeutic interventions.
Microbiome
One of the most exciting discoveries involves the intricate ways that gut microbes and host genetics interact to control physiology and metabolism. The more than 600 microbial species alone and together process dietary intake in essential ways to host physiology. Microbial dysbiosis is a major contributor to host dysfunction through their diverse effects on human metabolism [47] . These effects depend heavily on as yet unidentified host genetic factors [48] [49] [50] [51] [52] 53 & ]. Mouse models will continue to be essential for these studies because combinations of fecal transplants as well as host genetic manipulations can be used to dissect mechanistic relations in controlled ways that are highly relevant to public health but difficult to conduct in human populations.
GENETIC RESOURCES
Over the last 15 years, many mouse genetic resource populations have been reported. These have revolutionized studies of genetically complex traits. They have been used for discovering QTLs, and also for studying epigenetics and systems biology. Developing effective strategies for leveraging these complementary resources will be an important theme in the coming years as we learn how to most effectively utilize these reference populations.
Collaborative cross
The collaborative cross is an eight-way mouse recombinant inbred strain panel that is being developed as a resource for mammalian system genetics [54] . The collaborative cross strains are derived from eight diverse founder strains, including five classical inbred strains that are important as disease models and three wild-derived strains representing the three Mus musculus subspecies. The eight founder strains capture a level of genetic diversity unsurpassed by any other extant mouse resource. Currently, approximately 70 collaborative cross strains have been derived and are available to researchers. The strains have enabled mapping of phenotypes related to diabetes [55] , hepatic steatosis [56] , drug disposition [57] , and other metabolic phenotypes.
Diversity outbreds
The diversity outbreds are a heterogeneous stock derived from the same eight founder strains as the collaborative cross, resulting in a population with the same array of allelic polymorphisms but present in a wider variety of combinations [58 && ]. The diversity outbreds are maintained as a randomized breeding colony with a population size of 180 pairs. At present, the diversity outbreds colony has reached 23 generations of outcrossing and can simultaneously achieve high resolution and high power to detect small allelic effects. A drawback of the diversity outbreds is that each animal is genetically unique and not reproducible. However, genetic loci that are mapped in the diversity outbreds can be replicated in collaborative cross strains or their F1 progeny to provide stable models for validation and in-depth characterization. It is still early days and there are many ongoing studies. A recent report on the genetics of protein abundance demonstrates the power of this resource [59] .
Hybrid mouse diversity panel and recombinant inbred strains
When two inbred strains are bred to one another, through meiotic recombination the chromosomes of their offspring contain a mosaic of segments from the founder strains. This mosaic can be fixed by inbreeding, creating panels of unique recombinant inbred strains. The strains need only be genotyped once and, as inbred strains, offer unlimited biological replication. Panels of inbred strains have been used for systems genetics projects, where many phenotypes have been mapped and the data integrated into biological networks. Two recent examples are the BXD panel (from C57BL/6 Â DBA) [60] [61] [62] and the hybrid mouse diversity panel [63] . The hybrid mouse diversity panel has had remarkable success in identifying genes related to a broad spectrum of human metabolic disease, including atherosclerosis [64] , obesity [65] , diet responsiveness, insulin resistance and diabetes [66] , plasma lipids [65] , and hepatic steatosis [67 & ]. The ability to carry out unlimited phenotyping on the same panel of recombinant inbred strains enables the development of causal networks that connect various phenotypes, the ultimate goal of systems biology [63] .
Chromosome substitution strains
A CSS (also known as a consomic strain) has a chromosome in the host strain replaced with the corresponding strain from a donor strain. The resulting inbred strain is homozygous for the substituted chromosome on an inbred strain background and differs from the original host strain by a single chromosome. A complete panel of substituted chromosomes, which has 22 strains, one for each of the 19 autosomes, the X and Y chromosomes and the mitochondria, neatly partition the genome into nonoverlapping units based on the genome's chromosome structure. Several panels have been made from commonly used inbred strains [68] . QTLs can be detected simply by comparing each CSS with the host strain, testing for a significant phenotypic difference that implicate at least one QTL on the substituted chromosome. These strains are inbred, congenic strains are readily derived from them, precisely defined test and control groups can be arranged, and functional studies can be undertaken simultaneously with gene discovery efforts. This enables rigorous study of the molecular, biochemical, and physiological mechanisms controlling the phenotypes of interest.
CSSs have been used to study diet-induced metabolic conditions, where genes on the majority of chromosomes have been shown to affect obesity, glucose homeostasis, dyslipidemia, and liver disease and several genes have been identified [30] . Also important is discovery of precisely defined comorbidities involving obesity, cholesterol levels, insulin resistance, and fatty liver, where many of the CSSs have unique combinations of these traits [69] . Finally, CSSs have been used to identify modifier genes that control phenotypic outcomes, with a recent example being the Moda1 locus, which suppresses diabetes in the hepatocyte nuclear factor 1a model of MODY3 (maturity onset diabetes of the young type 3) [70] .
Chemical mutagenesis
Chemical mutagenesis has been used to induce mutations in mice. These can cause both gain-offunction (usually dominant) or loss-of-function (usually recessive) phenotypes. This approach led to the discovery of nicotinamide nucleotide transhydrogenase as a regulator of insulin secretion [71] . Follow-up studies showed that the C57BL6/J strain (in contrast to C57BL6/N) has a natural deletion of this gene [72] .
Engineered mutations
The ability to delete genes in a tissue-specific manner has produced numerous profound and often surprising new insights. GLUT4 is the insulinregulated glucose transporter expressed in muscle and adipose tissue. Although muscle is the tissue that makes the largest contribution to insulinstimulated glucose clearance, deletion of Glut4 in adipose tissue had as much of an effect on insulin resistance as the Glut4 deletion in muscle [73] . This is largely because of the endocrine functions of adipose tissue; in response to reduced Glut4 expression, adipose tissue produces hormones that affect whole-body insulin signaling [21] .
Early studies showed that administration of insulin in the brain regulates the ability of circulating insulin to suppress hepatic glucose production [74] . Deletion of the insulin receptor in the brain abolishes the ability of insulin to suppress hepatic glucose production [75] . Now it is well established that the brain regulates metabolism in numerous organs. Many of the actions of hormones on metabolism occur through the brain. For example, the suppression of glucagon secretion by leptin is primarily through its action in the brain [76] . A recent study showed that microbiome production of acetate regulates insulin secretion through an axis that includes the brain [77] .
INTEGRATION
Systems studies
These studies seek to define the networks of functional dependencies between genetic variants and multilevel phenotypes from RNA expression patterns to proteins and metabolites and finally to organs and metabolic outcomes. This integrated view complements reductionist approaches [1, 2] . These reductionist approaches identify the nature and function of elements that compose the foundation of complex biology, whereas systems studies define the context and consequence of the collective and integrated action of these elements focusing on such essential systems properties as robustness, resilience, homeostasis, hysteresis, and criticality [78] .
CONCLUSION
The foundation of scientific research is combining discovery with experimentation. Obviously, in humans, discovery is easy. Experimentation, by contrast, is difficult because test and control groups must be controlled in ways so they ideally differ only in single agents. Multifactorial designs are also possible but again rigorous design is needed to manage the genetic and environmental complexities. In model organisms, such control is feasible.
It has been proposed that computational analyses of big data, together with in-vitro studies with human materials, will suffice to provide the understanding that we seek to prevent disease and improve the human condition. However, many diseases and most phenotypes are not properties of single cell types in vitro. Many metabolic conditions, even those resulting from single-gene Mendelian conditions, involve multiple cell types across multiple organs, and thus are problems in systems biology [1, 2] . We therefore propose that an interdependency between humans and model organisms will emerge as the centerpiece of biomedical research. This relationship will be effective as long as the similarities and differences in development and physiology are fully identified and taken into account when designing studies in model organisms and extrapolating the results back to humans. Pioneering discoveries in the past both challenged and justified investments in technologies and resources now enable these systematic, integrated studies at genome and organismal scale.
A recent commentary predicts that 'modeling human complex traits in experimental organisms will become obsolete' [79] . The commentary goes on to say that 'humans will become a 'model organism' through exploiting new technologies such as tissuespecific cell lines and gene editing. ' We hope that the foregoing discussion will help to put this notion to rest.
